Lorista N tablets p / o 100mg + 12.5 mg, No. 90

• Arterial hypertension (for patients for whom combination therapy is indicated);

• Reducing the risk of cardiovascular morbidity and mortality in patients with arterial hypertension and left ventricular hypertrophy.

Inside, regardless of the meal.

LoristaЃ N 100 can be combined with other antihypertensive drugs.

Arterial hypertension. The recommended dose of LoristaЃ N 100 is 1 tab. (100 / 12.5 mg) once a day. As a rule, the drug is prescribed in the absence of an adequate therapeutic effect of the drug LoristaЃ N (50 / 12.5 mg).

The maximum antihypertensive effect is achieved within 3 weeks of therapy. In elderly patients, patients with impaired renal function (Cl creatinine 30-50 ml / min), including patients on dialysis, adjustment of the initial dose is not required.

Reducing the risk of cardiovascular morbidity and mortality in patients with arterial hypertension and left ventricular hypertrophy. The initial and maintenance dose of losartan is 50 mg once a day. Patients who failed to achieve target blood pressure levels while using losartan at a dose of 50 mg / day need to select therapy by combining losartan with low doses of hydrochlorothiazide (12.5 mg). If necessary, it is possible to increase the dose of losartan to 100 mg in combination with hydrochlorothiazide at a dose of 12.5 mg / day.

The recommended dose of LoristaЃ N 100 is 1 tab. (100 / 12.5 mg) once a day. The maximum daily dose is 1 table. LoristaЃ N 100.

Impaired renal function. No dose adjustment is required.

Elderly patients. No dose adjustment is required.

Film-coated tablets

Active substances:

Hydrochlorothiazide - 12.5 mg

Losartan potassium - 100 mg

Excipients: pregelatinized starch - 59.2 mg; MCC - 137.1 mg; lactose monohydrate - 88.4 mg; magnesium stearate - 2.8 mg film shell: hypromellose - 8 mg; macrogol 4000 - 0.8 mg; titanium dioxide (E171) - 2.4 mg; talc - 0.8 mg

• Anuria;

• severe renal failure (CC <30 ml / min);

• severe liver dysfunction;

• pregnancy;

• lactation period (breastfeeding);

• children and adolescents up to 18 years old;

• hypersensitivity to drug components; hypersensitivity to sulfonamide derivatives.

Carefully

Violations of the water and electrolyte balance of the blood (hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypokalemia), bilateral stenosis of the renal arteries, stenosis of the artery of the only functioning kidney, condition after kidney transplantation, hypercalcemia, hyperuricemia and / or gout, aggravated allergic diseases, asthma connective tissue (including systemic lupus erythematosus), simultaneous use of NSAIDs, including COX-2 inhibitors, diabetes mellitus, liver dysfunction, renal dysfunction (CC from 30-50 ml / min), hypovolemia (including against the background of taking diuretics in high doses), an acute attack of angle-closure glaucoma.

Tablets, film-coated from yellow to yellow with a greenish tinge, oval, slightly biconvex, with a line on one side; cross-sectional view of the tablet - the core of the tablet is white.

Composition:

Active ingredients:

Losartan potassium - 50 mg

Hydrochlorothiazide - 12.5 mg

Excipients : pregelatinized starch - 34.92 mg, microcrystalline cellulose - 87.7 mg, lactose monohydrate - 63.13 mg, magnesium stearate - 1.75 mg.

The composition of the film shell: hypromellose - 5 mg, macrogol 4000 - 0.5 mg, quinoline yellow dye (E104) - 0.11 mg, titanium dioxide (E171) - 1.39 mg, talc - 0.5 mg.

Oval tablets, with a biconvex surface, film-coated white

Active ingredients:

Losartan potassium - 100.00 mg

Hydrochlorothiazide - 12.50 mg

Excipients : pregelatinized starch, microcrystalline cellulose, lactose monohydrate, magnesium stearate,

Shell composition: hypromellose, macrogol 4000, titanium dioxide (E171), talc

Clinical and pharmacological group: Antihypertensive drug

Pharmaco-therapeutic group: Antihypertensive combined agent (angiotensin II receptor blocker + diuretic)

pharmachologic effect

Combined antihypertensive agent. Losartan and hydrochlorothiazide have an additive antihypertensive effect, lowering blood pressure to a greater extent than each of the components alone.

Losartanis a selective antagonist of angiotensin II receptors (type AT1) for oral administration. In vivo and in vitro, losartan and its pharmacologically active metabolite E-3174 block all physiologically significant effects of angiotensin II on AT1 receptors, regardless of the pathway of its synthesis: it leads to an increase in blood plasma renin activity, reduces the concentration of aldosterone in blood plasma. Losartan indirectly causes the activation of AT2 receptors by increasing the concentration of angiotensin II. Does not inhibit the activity of kininase II, an enzyme that is involved in the metabolism of bradykinin. Reduces OPSS, pressure in the pulmonary circulation, reduces afterload on the myocardium, has a diuretic effect. Prevents the development of myocardial hypertrophy, increases exercise tolerance in patients with chronic heart failure (CHF).Taking losartan 1 time / day leads to a statistically significant decrease in systolic and diastolic blood pressure.

Losartan evenly controls blood pressure throughout the day, while the antihypertensive effect corresponds to the natural circadian rhythm. The decrease in blood pressure at the end of the dose of the drug was approximately 70-80% of the maximum effect of losartan, 5-6 hours after oral administration. There is no withdrawal syndrome.

Losartan has no clinically significant effect on heart rate, has a moderate and transient uricosuric effect.

Hydrochlorothiazide is a thiazide diuretic, the diuretic effect of which is associated with impaired reabsorption of sodium, chlorine, potassium, magnesium, water in the distal nephron; delays the excretion of calcium ions, uric acid. It has an antihypertensive effect, the action of which develops due to the expansion of arterioles. Has practically no effect on normal blood pressure. The diuretic effect occurs in 1-2 hours, reaches a maximum after 4 hours and lasts 6-12 hours. The maximum antihypertensive effect occurs in 3-4 days, but it may take 3-4 weeks to achieve the optimal therapeutic effect.

Due to the diuretic effect, hydrochlorothiazide increases the activity of plasma renin, stimulates the secretion of aldosterone, increases the concentration of angiotensin II and reduces the concentration of potassium in the blood plasma. Taking losartan blocks all the physiological effects of angiotensin II and, due to the suppression of the effects of aldosterone, may help reduce the loss of potassium associated with taking a diuretic. Hydrochlorothiazide causes a slight increase in the concentration of uric acid in the blood; the combination of losartan and hydrochlorothiazide helps to reduce the severity of diuretic-induced hyperuricemia.

Pharmacokinetics

The pharmacokinetics of losartan and hydrochlorothiazide with simultaneous use does not differ from that when they are used with monotherapy.

Losartan

After oral administration, losartan is well absorbed from the gastrointestinal tract. Undergoes significant metabolism during the 'first pass' through the liver, forming a pharmacologically active carboxylated metabolite (E-3174) and inactive metabolites. Bioavailability is approximately 33%. Average Cmax of losartan and its active metabolite are reached after 1 hour and after 3-4 hours, respectively. Losartan and its active metabolite bind to blood plasma proteins (mainly albumin) by more than 99%. Vd of losartan is 34 liters. Very poorly penetrates the BBB.

Losartan is metabolized to form an active (E-3174) metabolite (14%) and inactive, including two main metabolites formed by hydroxylation of the butyl group of the chain and a less significant metabolite, N-2-tetrazole glucuronide. Plasma clearance of losartan and its active metabolite is approximately 10 ml / sec (600 ml / min) and 0.83 ml / sec (50 ml / min), respectively. The renal clearance of losartan and its active metabolite is about 1.23 ml / sec (74 ml / min) and 0.43 ml / sec (26 ml / min). T1 / 2 of losartan and the active metabolite is 2 hours and 6-9 hours , respectively. It is excreted mainly with bile through the intestines - 58% , by the kidneys - 35% . Does not cumulate.

When taken orally in doses up to 200 mg, losartan and its active metabolite have linear pharmacokinetics.

Hydrochlorothiazide

After oral administration, the absorption of hydrochlorothiazide is 60-80%. Cmax in blood plasma is achieved within 1-5 hours after oral administration. Plasma protein binding - 64%. Penetrates the placental barrier. Excreted in breast milk. Hydrochlorothiazide is not metabolized and is rapidly excreted by the kidneys. T1 / 2 is 5-15 hours. At least 61% of the dose taken orally is excreted unchanged within 24 hours.

Indications

Ј Arterial hypertension (for patients for whom combination therapy is indicated);

Ј Reducing the risk of cardiovascular morbidity and mortality in patients with arterial hypertension and left ventricular hypertrophy.

Dosage regimen

The method of application and dosage regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of a particular drug with the indications for use and the dosage regimen.

I take it orally, regardless of the meal.

The recommended dose of the combination in terms of losartan is 50-100 mg 1 time / day. The maximum dose is 100 mg 1 time / day.

The maximum antihypertensive effect is achieved within 3 weeks of therapy.

Side effect

From the immune system: rarely - anaphylactic reactions, angioedema (including edema of the larynx and tongue, causing obstruction of the airways and / or edema of the face, lips, pharynx), urticarial rash.

On the part of the hematopoietic system: infrequently - anemia, Shenlein-Henoch purpura, ecchymosis, hemolysis, agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, thrombocytopenia.

From the nervous system: often - headache, dizziness, insomnia, fatigue; infrequently - migraine, anxiety, confusion, depression, sleep disturbances, memory impairment, drowsiness, nervousness, paresthesia, tremor, fainting.

From the side of the cardiovascular system: often - orthostatic hypotension (dose-dependent), palpitations, tachycardia; infrequently - II degree AV block, chest pain, myocardial infarction, arrhythmias; rarely - vasculitis.

From the respiratory system: often - cough, upper respiratory tract infections, sinusitis, swelling of the nasal mucosa, nasal congestion; infrequently - pharyngitis, laryngitis, rhinitis, dyspnea, bronchitis, epistaxis.

From the digestive system: often - diarrhea, dyspepsia, nausea, vomiting, abdominal pain; rarely - hepatitis, liver dysfunction.

From the urinary system: infrequently - urinary tract infections, frequent urination, nocturia, glucosuria.

On the part of the reproductive system: infrequently - weakening of libido, decreased potency.

From the senses: infrequently - blurred vision, burning sensation in the eyes, conjunctivitis.

On the part of the skin: often - alopecia, dry skin, erythema, photosensitivity, increased sweating; infrequently - urticaria, itchy skin.

From the musculoskeletal system: often - myalgia, back pain; infrequently - arthralgia.

Others: often - asthenia, weakness, peripheral edema; infrequently - anorexia, exacerbation of the course of gout.

On the part of laboratory parameters: often - hyperkalemia, a slight decrease in the concentration of hemoglobin and hematocrit; infrequently - a moderate increase in the concentration of urea and creatinine in the blood plasma, hyperglycemia, hyperuricemia, disturbances in the water-electrolyte balance; rarely - increased ALT activity; very rarely - an increase in the activity of ACT and the concentration of bilirubin.

Contraindications for use

Anuria; severe renal failure (CC <30 ml / min); severe liver dysfunction; pregnancy; lactation period (breastfeeding); children and adolescents up to 18 years old; hypersensitivity to drug components; hypersensitivity to sulfonamide derivatives.

Carefully

Violations of the water and electrolyte balance of the blood (hyponatremia, hypochloremic alkalosis, hypomagnesemia, hypokalemia), bilateral stenosis of the renal arteries, stenosis of the artery of the only functioning kidney, condition after kidney transplantation, hypercalcemia, hyperuricemia and / or gout, aggravated allergic diseases, asthma connective tissue (including systemic lupus erythematosus), simultaneous use of NSAIDs, including COX-2 inhibitors, diabetes mellitus, liver dysfunction, renal dysfunction (CC from 30-50 ml / min), hypovolemia (including against the background of taking diuretics in high doses), an acute attack of angle-closure glaucoma.

Application during pregnancy and lactation

Use during pregnancy and lactation (breastfeeding) is contraindicated.

Application for violations of liver function

Contraindicated in severe liver dysfunction.

With caution for mild and moderate liver dysfunctions.

Application for impaired renal function

Contraindicated in severe renal failure (CC <30 ml / min).

With caution in case of mild and moderate renal dysfunction (CC from 30-50 ml / min).

Application in children

The drug is contraindicated for use in children and adolescents under the age of 18 years.

Use in elderly patients

The drug is approved for use in elderly patients

special instructions

Against the background of the use of losartan, reversible renal dysfunction, including renal failure, which disappear after losartan is discontinued, are possible. Drugs affecting the RAAS can lead to an increase in the concentration of urea and creatinine in the blood plasma in patients with bilateral renal artery stenosis or stenosis of a solitary kidney artery. These changes in renal function may be reversible and disappear after discontinuation of therapy.

In patients with impaired renal function treated with NSAIDs (including COX-2 inhibitors), therapy with angiotensin II receptor antagonists may further worsen renal impairment, including acute renal failure, which is usually reversible, and increase plasma potassium levels in patients with pre-existing renal impairment. This combination is recommended to be used with caution, especially in elderly patients. Patients should receive a sufficient amount of fluid, as well as monitor kidney function before and after starting treatment with this combination.

The condition of patients should be monitored in order to timely detect clinical signs of violations of water and electrolyte balance, for example, dehydration, hyponatremia, hypochloremic alkalosis, hypomagnesemia or hypokalemia, which may develop against the background of concomitant diarrhea or vomiting. In such patients, monitoring of the content of electrolytes in the blood plasma is necessary.

Thiazide diuretic therapy can impair glucose tolerance. In some cases, it may be necessary to adjust the doses of hypoglycemic agents for oral administration and / or insulin.

Thiazides can reduce the excretion of calcium by the kidneys and cause a short-term and insignificant increase in the concentration of calcium in the blood plasma. Severe hypercalcemia may indicate latent hyperparathyroidism.

Due to the effect of thiazides on calcium metabolism, their use can distort the results of the study of the function of the parathyroid glands, therefore, before the study of the function of the parathyroid glands, the thiazide diuretic should be canceled.

An increase in the concentration of cholesterol and triglycerides in the blood may also be associated with therapy with thiazide diuretics.

In some patients, the use of thiazide diuretics can lead to hyperuricemia and / or the development of gout. Since losartan reduces the concentration of uric acid, its combination with hydrochlorothiazide reduces the severity of diuretic-induced hyperuricemia.

Hydrochlorothiazide is a sulfonamide that can cause an idiosyncratic reaction leading to the development of an acute attack of angle-closure glaucoma.

In patients receiving thiazide diuretics, hypersensitivity reactions can be observed even in the absence of a history of indications of allergic reactions or bronchial asthma. There are reports of the development of exacerbation or progression of systemic lupus erythematosus against the background of the use of thiazide diuretics.

Influence on the ability to drive vehicles and mechanisms

Care must be taken when driving vehicles and working with other technical devices that require increased concentration of attention and speed of psychomotor reactions.

Drug interactions

ќдновременное применение с калийсберегающими диуретиками (спиронолактон, эплеренон, триамтерен, амилорид), препаратами кали¤ или калийсодержащими заменител¤ми поваренной соли, а также применение других препаратов, способствующих повышению концентрации кали¤ в плазме крови, увеличивают риск развити¤ гиперкалиемии.

Ќѕ¬—, в т.ч. селективные ингибиторы ?ќv-2 могут снижать эффект диуретиков и других гипотензивных средств, включа¤ лозартан.

јнтигипертензивный эффект лозартана, как и других гипотензивных средств, может быть снижен при применении индометацина.

?война¤ блокада –јј—, т.е. добавление ингибитора јѕ‘ к терапии антагонистом рецепторов ангиотензина II, возможна только в отдельных случа¤х под тщательным контролем функции почек.

” пациентов с атеросклерозом, сердечной недостаточностью или сахарным диабетом с поражением органов-мишеней, двойна¤ блокада –јј— (при одновременном применении антагонистов рецепторов ангиотензина II, ингибиторов јѕ‘ или алискирена) сопровождаетс¤ повышенной частотой развити¤ артериальной гипотензии, обмороков, гиперкалиемии и нарушений функции почек (включа¤ острую почечную недостаточность) в сравнении с применением препарата одной из перечисленных групп.

¬озможно снижение выведени¤ ионов лити¤. ѕоэтому при одновременном применении антагонистов рецепторов ангиотензина II с сол¤ми лити¤ следует тщательно контролировать сывороточные концентрации лити¤.

ѕри одновременном применении с тиазидными диуретиками такие лекарственные средства, как этанол, барбитураты и опиоидные анальгетики могут потенцировать риск развити¤ ортостатической гипотензии.

ѕри одновременном применении возможно усиление гипогликемического действи¤ гипогликемических средств дл¤ приема внутрь (производные сульфонилмочевины) и/или инсулина у пациентов с сахарным диабетом; при таких комбинаци¤х возможно повышение толерантности к глюкозе, что может потребовать коррекции доз гипогликемических средств дл¤ приема внутрь и/или инсулина.

ѕри одновременном применении с другими гипотензивными средствами - аддитивный эффект.

¬сасывание гидрохлоротиазида нарушаетс¤ в присутствии колестирамина и колестипола.

ѕри одновременном применении с v —, ј “v наблюдаетс¤ выраженное снижение содержани¤ электролитов, в частности гипокалиеми¤.

Ќаблюдаетс¤ снижение выраженности терапевтического эффекта гидрохлоротиазида на фоне применени¤ прессорных аминов (например, эпинефрин (адреналин), норэпинефрин (норадреналин)).

vидрохлоротиазид усиливает эффект миорелаксантов недепол¤ризующего типа действи¤ (например, тубокурарина хлорида).

?иуретики снижают почечный клиренс лити¤ и повышают риск развити¤ токсического действи¤ лити¤. ќдновременное применение не рекомендуетс¤.

ѕри одновременном применении с барбитуратами, наркотическими анальгетиками, антидепрессантами, этанолом повышаетс¤ риск развити¤ ортостатической гипотензии.

ѕрепараты, примен¤емые дл¤ лечени¤ подагры (пробенецид, сульфинпиразон и аллопуринол): гидрохлоротиазид способен повышать сывороточную концентрацию мочевой кислоты, поэтому может потребоватьс¤ коррекци¤ дозы препаратов урикозурического действи¤ - повышение дозы пробенецида или сульфинпиразона. ќдновременное применение тиазидных диуретиков может повышать частоту реакций повышенной чувствительности к аллопуринолу.

Concomitant use with cyclosporine may increase the risk of hyperuricemia and exacerbate the course of gout.

Anticholinergics (eg, atropine, biperiden) increase the bioavailability of thiazide diuretics by reducing gastrointestinal motility and gastric emptying.

Thiazide diuretics can reduce the renal excretion of cytotoxic drugs (cyclophosphamide, methotrexate) and enhance their myelosuppressive effect.

In the case of the use of salicylates in high doses, hydrochlorothiazide may increase their toxic effect on the central nervous system.

There are limited data on the development of hemolytic anemia with the simultaneous use of hydrochlorothiazide and methyldopa.

Hypokalemia or hypomagnesemia caused by thiazide diuretics can lead to the development of arrhythmias with the use of cardiac glycosides.